Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239004 | 0.83 | ADRB1 (0.71) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31051961 | 0.81 | ADRB1 (0.69) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052066 | 0.80 | ADRB1 (0.67) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052065 | 0.80 | ADRB1 (0.67) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL13499602 | 0.80 | ADRB1 (0.67) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052020 | 0.80 | ADRB1 (0.67) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| Eltoprazine SCHEMBL177715 | 0.80 | ADRB1 (1.00) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31051847 | 0.80 | ADRB1 (0.67) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| Eltoprazine SCHEMBL679616 | 0.79 | ADRB1 (0.97) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| Eltoprazine SCHEMBL31235563 | 0.79 | ADRB1 (0.97) | ADRB1HTR1AALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-1858875-A2 | ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION | Solvay Pharmaceuticals B.V. (NL) | 2007-11-28 | — | — | EP | claimed |
| US-20060194971-A1 | Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-31 | — | — | US | claimed |
| WO-2006089861-A2 | ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-31 | — | — | WO | claimed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | disclosed |
| US-7977374-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-12 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-1926721-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-06-04 | — | — | EP | disclosed |
| EP-1858875-A2 | ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION | Solvay Pharmaceuticals B.V. (NL) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007029035-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
| US-20060194971-A1 | Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-31 | — | — | US | disclosed |
| WO-2006089861-A2 | ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC2, HDAC11 | ADRB1 3170/4885HTR1A 1960/4885ALDH1A1 398/4885 |
| US-20060194971-A1 | Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission | MAOB, MAOA, DAO | ADRB1 525/4885HTR1A 371/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.